NMPA grants conditional approval to Sinopharm’s COVID-19 vaccine

State Council of the PRC carries the official instrument or communique. Reuters records the same dated act independently.

Established: a 31 December 2020 NMPA conditional approval of Sinopharm’s BBIBP-CorV.

Not established: a unique later infection-fatality coefficient from New Year’s Eve, or that the vaccine was mRNA.

Sinopharm manufactured. He politically owned vaccine public-goods pledges and the state group, not the reviewer’s signature.. A later repeal, court stay, or successor order would be a different Fact with a different date. That pair identifies NMPA grants conditional approval to Sinopharm’s COVID-19 vaccine, not a later speech about NMPA grants conditional approval to Sinopharm’s COVID-19 vaccine.

Co-authors and later implementers named in Context remain on the file. If a later repeal, stay, or successor decree exists, it needs its own date and its own row. The contribution described on this Person row is limited to NMPA authorised. Sinopharm manufactured. That limit is the alternative to treating office-holding as authorship of every later series. The National People’s Congress, the State Council, provincial governments, the People’s Liberation Army, Hong Kong’s executive, and foreign counterparties share specific files. Allegation is not a completed judgment. An OHCHR assessment is not a criminal conviction. A white paper is not a census. A UN pledge is not a delivered emissions path.